Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - mupirocin as calcium - ointment - mupirocin as calcium 2 %w/w - mupirocin - mupirocin - the elimination of nasal carriage of staphylococci, including methycillin-resistant staphylococus aureus (mrsa).

United States - English - NLM (National Library of Medicine)

biomes pharmaceuticals llc - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - mupirocin - ointment - mupirocin 20 mg/g - antibiotics and chemotherapeutics for dermatological use

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - mupirocin calcium, quantity: 21.5 mg/g (equivalent: mupirocin, qty 20 mg/g) - ointment - excipient ingredients: white soft paraffin; bis-diglyceryl polyacyladipate-2 - bactroban (mupirocin) nasal ointment is indicated for the elimination of nasal carriage of staphylococci including methicillin resistant staphylococcus aureus (mrsa).

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - mupirocin - nasal ointment - mupirocin 20 mg/g - antibiotics and chemotherapeutics for dermatological use

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti

Kenya - English - Pharmacy and Poisons Board

belea pharmacy ltd p.o.box 6397-00200 nairobi, kenya - mupirocin - ointment - each gram contains: mupirocin usp 20mg - mupirocin

Kenya - English - Pharmacy and Poisons Board

klm laboratories pvt ltd. 1004, hubtown viva, western express highway, - mupirocin - ointment - mupirocin usp 2% - mupirocin

Kenya - English - Pharmacy and Poisons Board

mupirocin - ointment - mupirocin 2% w/w - mupirocin

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - mupirocin - ointment - 2% w/w - mupirocin 2% w/w